Loading…

A pair of studies reports liver-targeted antisense oligonucleotide and silencing RNA therapies for inherited disorders that impair lysine breakdown, including ALDH7A1 deficiency and glutaric aciduria type I. The researchers used an N-acetylgalactosamine conjugate to direct the treatment to liver cells and knock down the AASS gene.
This is a biomedical research story with no link to feed, grain or oilseed supply, demand or prices.
Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.